- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20:10 | Proof Over Promise: What a DTP Program Actually Looks Like When It's Working | ||
| 17:10 | As Dupixent keeps sales churning, Sanofi doubles down on R&D re-work | ||
| 17:10 | AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink | ||
| 16:10 | Pfizer looks to reroute supply after flooding sidelined India injectables plant | ||
| 14:10 | Fierce Pharma Asia-The hunt for Enhertu's successor; ESMO data from Merck, BMS, Takeda and more | ||
| Do | Lenz reports 75% workforce cut, CEO shakeup alongside Q3 earnings update | ||
| Do | Lilly breaks down Medicare Bridge boon as GLP-1 sales drive another guidance lift | ||
| Do | Women 'still waiting' for healthcare to earn their trust: report | ||
| Do | AZ takes a 'time out' with former teen TV star in biomarker testing push | ||
| Do | HCPs Aren't Ignoring Your Science. They're Ignoring How (and When) You Deliver It | ||
| Do | Merck outlines 2027 as 'another year of investment' despite recent clinical wins | ||
| Do | Bristol Myers' Cobenfy performance called into question amid overall Q3 revenue beat | ||
| Do | Lonza rounds out Swiss ADC expansion's scope with mid-scale capabilities | ||
| Do | Kennedy's HHS relaxes enforcement on 6 popular wellness peptides | ||
| Do | Geron's Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid | ||
| Mi | 'Numbers speak for themselves': Biogen's Apellis buyout fuels best quarter since 2020 | ||
| Mi | Lilly combines global markets under new leadership role as 36-year veteran retires | ||
| Mi | After GSK's Q3 approval spate, Hibsago preps for 'concentrated' US hep B launch | ||
| Mi | Blue Matter 'turbocharges' global reach of comms agency Cognite with acquistion | ||
| Mi | GSK vows not to 'park crap on Page 41' in transparency push | ||
| Mi | Amgen hit with FDA warning letter for 'misleading' Vectibix promotion | ||
| Mi | Supernus shreds ADHD stigma with Olympic snowboarder Chloe Kim | ||
| Mi | Eversana combines forces with UK-based AI health economics research firm Estima in acquisition | ||
| Mi | Eli Lilly surges up diabetes reputation rankings to close in on Novo | ||
| Di | Teva telegraphs 61 job cuts amid plans to close 'underutilized' New Jersey plant |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.